Biotech startup Goldfinch Bio pulls in $55 mln

Cambridge, Massachusetts-based Goldfinch Bio, a biotech company focused on discovering and developing precision therapies for patients with kidney disease, has raised $55 million in Series A funding. The investor was Third Rock Ventures.

North AmericaUSBriefs